

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3974558
<b>Application Number:</b>	10657363
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3135
<b>Title of Invention:</b>	Ultra high affinity neutralizing antibodies
<b>First Named Inventor/Applicant Name:</b>	James F. Young
<b>Customer Number:</b>	20583
<b>Filer:</b>	Tamera Weissner/Eric Baclig
<b>Filer Authorized By:</b>	Tamera Weissner
<b>Attorney Docket Number:</b>	10271-159-999
<b>Receipt Date:</b>	22-SEP-2008
<b>Filing Date:</b>	08-SEP-2003
<b>Time Stamp:</b>	20:04:28
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	LAMPRECHT_J_Infect_Dis_211.pdf	508051 5a52ec528075d8ed9f231246e61ef390fe8f 5579	no	7

### Warnings:

Information:
--------------

2	NPL Documents	LANDRY_Infec_Dis_166A_969.pdf	238876 03e43923913a021190b1fd15012af32c6c0 086660	no	2
---	---------------	-------------------------------	---	----	---

**Warnings:****Information:**

3	NPL Documents	LOBUGLIO_PNAS_4220.pdf	511367 0f95a1bccc4390d4fa69ff11ac90d05922fe 14	no	5
---	---------------	------------------------	--	----	---

**Warnings:****Information:**

4	NPL Documents	MACDONALD_N_Eng_J_Med_397.pdf	559029 0ef9f7390520065116e1a11e14d444dabfc 98e0	no	4
---	---------------	-------------------------------	---	----	---

**Warnings:****Information:**

5	NPL Documents	MALLEY_J_Infect_Dis_1555.pdf	559932 ccf157730feeb295e4b803c5e4d052e0 9de0b	no	7
---	---------------	------------------------------	---	----	---

**Warnings:****Information:**

6	NPL Documents	MARKS_Biotechnology_779.pdf	607390 cd37381125bb2a2f044196bf0f291378192 0fc138	no	5
---	---------------	-----------------------------	---	----	---

**Warnings:****Information:**

7	NPL Documents	MCARTHUR-VAUGHAN_J_Med_Primatol_61.pdf	1180079 a8004be349934ff63862acecf95a21a0 6523	no	14
---	---------------	--	---	----	----

**Warnings:****Information:**

8	NPL Documents	MEDIMMUNE_BioSpace_Beat_Nov_6_2006.pdf	478035 67c13d0be2b55ad18db35447d57393761 03c0b	no	4
---	---------------	--	--	----	---

**Warnings:****Information:**

9	NPL Documents	MEDIMMUNE_BioSpace_Beat_Sept_1_2005.pdf	458829 dat140fb0bd3f805d6790411cef1f6e522d 186	no	3
---	---------------	---	--	----	---

**Warnings:****Information:**

10	NPL Documents	MEDIMMUNE_Synagis_Package_Insert_1999.pdf	202018 cbfa09227acef6ef70fa1d13fe0e123516e3 5eb1	no	1
----	---------------	---	--	----	---

**Warnings:****Information:**

11	NPL Documents	MEDIMMUNE- INC_Synagis_Package_Insert_2 002.pdf	265380 e502d012b4c264fb1b6e022209294912f68 b55409	no	1
<b>Warnings:</b>					

**Information:**

12	NPL Documents	MEISSNER_Antimicrob_Agents _Chemother_1183.pdf	621945 0494db14c65105c4209ab295e53d7c47 e380b	no	6
<b>Warnings:</b>					

**Information:**

13	NPL Documents	Motavizumab_vs_Palivizumab_ Inpharma_5.pdf	132849 2d48791a5212f2513109ff1b8324b10c a8408	no	1
<b>Warnings:</b>					

**Information:**

14	NPL Documents	MURPHY_J_Virol_3907.pdf	396728 46x31a0e20c062d1b1f2572fe2aef45a36e 66%	no	4
<b>Warnings:</b>					

**Information:**

15	NPL Documents	MURPHEY_Vaccine_185.pdf	374740 2e91491c60a10b4e01ec3037357863ed5 b19c2	no	5
<b>Warnings:</b>					

**Information:**

16	NPL Documents	NAVAS_J_Pediatr_348.pdf	547037 2e9ff0bb271de6786215d6f87e3c2a0e9bc a5ae	no	7
<b>Warnings:</b>					

**Information:**

17	NPL Documents	NGUYEN_Clin_Exp_Immunol_8 5.pdf	1203872 7b1edf2e07d8fa11395d66234dc5657845 d5c0	no	9
<b>Warnings:</b>					

**Information:**

18	NPL Documents	PALOMO_J_Virol_4199.pdf	1130966 517d92c02f294cafb9e9c0930900478fc7 79ff	no	8
<b>Warnings:</b>					

**Information:**

19	NPL Documents	Phys_Des_Ref_55th_Ed_1863. pdf	601114 011800ces1a0be36394c2b6d0cf70a71ef52 553e	no	3
<b>Warnings:</b>					

**Information:**

20	NPL Documents	PRINCE_Infect_Immун_81.pdf	471373 36aDec366647B32220ba6755351e99f81 2197	no	7
<b>Warnings:</b>					
<b>Information:</b>					
		Total Files Size (in bytes):		11049610	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>					
<p><b>New Applications Under 35 U.S.C. 111</b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>					
<p><b>National Stage of an International Application under 35 U.S.C. 371</b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					
<p><b>New International Application Filed with the USPTO as a Receiving Office</b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					